Etoposide with Carboplatin or Cisplatin

Phase 2

ASTRAZENECA PLC (AZNCF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AZNCFPhase 2$290.6B

Etoposide with Carboplatin or Cisplatin Phase 2 Est. Readout

Etoposide with Carboplatin or Cisplatin• Extensive-Stage Small-Cell Lung Cancer35

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

1 competitor in Extensive-Stage Small-Cell Lung Cancer

BNTXPumitamig

Phase 3

View Full Landscape

Drug Information

Target Indication

Extensive-Stage Small-Cell Lung Cancer

Clinical Trial

NCT05796089

Last updated: 8/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

propranololPhase 3

Migraine Without Aura

Quetiapine SRPhase 3

Anxiety Disorders

Ceftaroline fosamilPhase 3

Infections

Erlotinib 150/100 mgPhase 3

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Ticagrelor orodispersible tabletsPhase 3

ST Elevation Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts